

Index

Compiled by Linda English

- abducent nerve 8 Fig. 1.6, 9
Table 1.1, 19
- abscesses 121, 194, 196,
264, 308
- accessory nerve 8 Fig. 1.6,
9 Table 1.1, 118
- acetylcholine (ACh) 35, 40,
62, 74-75, 77 Table 3.1,
90-93 & Fig. 3.10 &
Table 3.3, 110, 226, 240
Fig. 7.7, 241
- acetylcholinesterase (AChE)
74, 90, 91 Fig. 3.10, 92,
241, 250
- action potentials 22, 42,
45-48 & Fig. 2.1 &
Table 2.2, 74 Fig. 3.3
- adenosine 77 Table 3.1, 78
- adenyl cyclase 227 & Fig.
7.3, 228 Box 7.1, 240
- adrenaline 93 Fig. 3.11, 99
- adrenocorticotrophic hormone
(ACTH) 108, 109, 149,
205, 223, 224 Fig. 7.1,
228 Box 7.1, 235, 239 &
Table 7.3, 244 Table 7.5
- adrenoleucodystrophy 212
Table 6.6, 307 Fig. 9.5
- Adult Memory and Informa-
tion Processing
Battery 179 Appendix
- adynamia 170
- agnosias 5, 28, 30 Table 1.4,
32, 37, 157 Table 5.1
- Aicardi malformation 142
Table 4.5
- AIDS/HIV infection 135 Box
4.5, 193, 194 Box 6.3,
197, 198, 218, 257, 308
- akathisia 132
- alcohol abuse 38, 82, 88, 97,
107, 135 Box 4.5, 136,
175, 207, 209, 254, 313
- foetal alcohol syndrome
142, 207
- withdrawal 73, 81, 83, 90,
102, 109, 127 Box 4.4,
134, 135 Box 4.6, 284
- alexia 30 Table 1.4, 157
Table 5.1, 172
- aluminium toxicity 145,
200, 208, 251
- Alzheimer's disease 102,
136, 145-146, 187, 193,
198-200 & Table 6.2,
217 Box 6.7
- aluminium and 145, 208
- cholinergic pathways and
35, 38, 75, 90, 92,
250-251
- as cortical dementia 133,
135 Box 4.5
- EEG and 250-251, 265-266,
292
- neuropsychological testing
172-173
- SPECT scanning 123, 313
- amino acids *see* excitatory
amino acids; inhibitory
amino acids
- amino methylisoxazole
propionic acid (AMPA)
receptors 77 Table 3.1,
81, 82 Fig. 3.6
- amnesia 38, 89, 134, 136,
145-146, 157 Table 5.1
- anterograde 38, 166-167,
171, 175
- cerebrovascular accidents
and 170, 171, 172
- post-traumatic (PTA) 144,
165, 166-168
- retrograde (RA) 38, 165-166,
168
- amphetamine 95, 97, 137
- amygdala 33 & Fig. 1.14, 34
& Fig. 1.15, 37, 38, 145,
199 Table 6.2, 202
- anencephaly 143, 214
- aneurysms 121, 140 Table 4.3,
189, 192, 303, 308-309
- angiography 303-304, 308,
309, 311, 314
- angular gyrus 3, 4 Fig. 1.2
- Annett's Handedness Ques-
tionnaire 181 Appendix
- anomia 30 Table 1.4, 31, 120
- anorexia nervosa 36, 108,
243, 244 Table 7.5
- anosognosia 30 Table 1.4, 32
- anterior cerebral artery 5 &
Fig. 1.3, 6 & Fig. 1.4,
170, 171, 190, 261
- anterior communicating
artery 5 & Fig. 1.3, 171
- anterior inferior cerebellar
artery 4, 5 Fig. 1.3
- anterior spinal arteries 4, 5
Fig. 1.3
- anticholinesterases 92 Table 3.3
- anticonvulsants 122, 129,
255, 279, 280
- antidepressants 80, 100, 106,
107
- tricyclic 74, 91, 99, 100
Table 3.5, 101, 104,
243, 255, 257
- anxiety states 83, 90, 102,
106, 107
- EEG and 283
- neuropsychological testing
163-164
- aphasias 5, 30 Table 1.4,
31, 120, 152, 170, 171
- apnoea, sleep 137, 285, 286
Fig. 1.14
- apomorphine 97
- aqueduct stenosis 217 Box
6.7, 307
- arecoline 92 Table 3.3, 93
- arginine vasopressin (AVP)
228 Box 7.1, 238 & Box
7.3, 239 & Table 7.3,
244 Table 7.5
- Arnold-Chiari malformation
142 Table 4.5, 215, 217
Box 6.7
- arousal 68, 69, 134, 168
- limbic system and 39-41
- noradrenaline and 98,
101, 102
- arteriovenous malformations
121, 124 Table 4.1, 127
Box 4.4, 140 Table 4.3,
170, 215, 303, 307, 308
- arteritis 124 & Table 4.1, 125
Table 4.2, 191 Box 6.1
- ascending reticular activating
system (ARAS) 39-40,
69, 249
- aspartate 62, 77 Table 3.1, 81
- association cortex 28, 29, 30
Table 1.4
- astrocytoma 203-204
- astrocytosis 187
- ataxia 27, 61, 114
- ataxia telangiectasia 216
Table 6.7
- atheroma 189, 191 Box 6.1,
303
- athetosis 26, 114, 130, 143
- auditory cortex 3, 4 Fig. 1.2,
10, 20 & Fig. 1.10, 29 &
Fig. 1.13, 67
- auditory evoked potentials 296
& Fig. 8.20, 297 Fig. 8.21
- auditory system 20-21 &
Fig. 1.10, 67-68
- autoinhibition 71, 72 Fig.
3.2, 73-74
- autonomic nervous system 33
Fig. 1.14, 35, 36, 37, 235
- autopagnosia 30 Table 1.4, 32
- Babinski sign 23 & Table
1.3, 190
- baclofen 89, 149
- barbiturates 85 Fig. 3.8, 87
& Table 3.2, 88, 89, 90,
110, 254, 255, 263

- basal ganglia 5, 6, 189, 209, 313
control of movement and 22, 25-26 & Fig. 1.12, 61-63 & Fig. 2.5, 129-130, 132, 147
neurotransmitters 62, 92, 95
limbic system and 33 Fig. 1.14, 35
basilar artery 4, 5 Fig. 1.3
Batten-Kuf's disease 211
Table 6.5
benign rolandic epilepsy 128, 251, 278
Benton Verbal Fluency Test 157 Table 5.1, 180
Appendix
benzhexol 92 & Table 3.3, 147
benzodiazepine/GABA
receptors 80, 81, 85-90 & Figs 3.8-3.9 & Table 3.2
benzodiazepines 106, 110, 133, 139, 149
EEG and 255, 256 Fig. 8.6, 279
beriberi 209
beta-blockers 105 Table 3.6, 125 Table 4.2
beta-endorphins 57, 77
Table 3.1, 108 Table 3.7, 223, 224 Fig. 7.1
Binswanger's disease 189, 309 & Fig. 9.6
birth trauma 127 & Box 4.4, 218
blepharospasm 130, 131, 132
Boston Diagnostic Aphasia Examination 179-180
Appendix
boxing 113, 127, 144, 310
brain
blood supply 3-7 & Figs 1.3-1.4
imaging 302-305
localisation of function concept 27-30 & Fig. 1.13 & Table 1.4, 152, 153, 155, 156, 174-175, 176-177
subdivisions and major surface features 2-3 & Figs 1.1-1.2
brainstem 2, 8-9 & Figs 1.6-1.7, 25-26 & Fig. 1.12, 39, 59, 131, 203, 263
brainstem auditory evoked potentials (BSAEPs) 21, 296-297 & Figs 8.20-8.21, 300
breathing disorders and sleep 137, 285, 286 Fig. 8.14
bremazocine 108 & Table 3.7
Broca's aphasia 30 Table 1.4, 31, 152, 171
Broca's speech area 3, 4
Fig. 1.2, 5, 31
Brodmann's areas 29 & Fig. 1.13, 30 Table 1.4
bromocriptine 97, 133, 147
Brown-Sequard syndrome 14
buprenorphine 109
buspirone 105 & Table 3.6, 106
calcarine sulcus 4 Fig. 1.2, 16, 17
calcitonin 223-224, 228 Box 7.1
calcitonin gene related peptide (CGRP) 223-224, 225
calcium channels 45, 48, 49, 81, 82 Fig. 3.6
carbamazepine 129, 255
carbidopa 93 Fig. 3.11, 94
carbon monoxide inhalation 208-209
catalytic hormone receptors 229
cataplexy 137, 279, 285
catecholamines 225, 236, 243 Table 7.4
synthesis 93 Fig. 3.11
see also dopamine;
noradrenaline
catechol-o-methyl transferase (COMT) 94, 95 Fig. 3.12, 99
Category Test 155, 157 Table 5.1, 161, 171, 182 Appendix
caudate nucleus 25 & Fig. 1.12, 26, 61, 62 & Fig. 2.5, 313 & Fig. 9.10
cell excitability and ion channels 42-48 & Tables 2.1-2.2 & Fig. 2.1
long-term changes in 49
cell membrane(s)
depolarisation 45-46 & Fig. 2.1
hormone receptors 225-226
ion distributions 43-44 & Table 2.1
resting membrane potential 44, 45
central nervous system (CNS)
assessment of function 112-121
clinical history 112-114 & Box 4.1
examination 114-121
lower functions 114-118 & Box 4.2
higher functions 118-121 & Box 4.2
examination of structure 188
symptoms and syndromes 123-149 & Tables 4.1-4.5 & Boxes 4.3-4.7
central pontine myelinolysis 207, 213 Box 6.6
central sulcus 2, 3 Fig. 1.1, 4 Fig. 2.2
cerebellum 2, 3 Fig. 1.1, 4, 313
and control of movement 26-27, 60-61 & Fig. 2.4
cerebellar syndrome 27
malformations 142 Table 4.5, 214, 215
and vestibular system 66, 67, 139
cerebral aqueduct 7 & Fig. 1.5, 217 Box 6.7, 307
cerebral cortex 27-33
and control of reflexes 63-64
dysplasia 140 Table 4.3
cerebral hemispheres 164
contingent negative variation and 291
disorganisation 140 Table 4.3, 307
schizophrenia and 161, 162, 257
specialisation 30-33, 38, 134, 153
left and language 31-32, 120, 161
cerebral infarction 5, 170, 189-192 & Boxes 6.1-6.2, 261, 303, 308
cerebral oedema 188, 206, 213 Box 6.6, 219
cerebral palsy 142-143
cerebral peduncles 2, 3 Fig. 1.1, 63
cerebrospinal fluid (CSF) 7-8, 73, 216-217 & Box 6.7, 306
cerebrovascular disorders 25, 83, 127 Box 4.4, 134, 137, 138 Box 4.7, 140 Table 4.3, 188-193 & Boxes 6.1-6.2
cerebrovascular accidents (CVAs): neuropsychological testing 170-172
EEG and 259-261, 262
Fig. 8.10
neuroradiology and 308-309 & Fig. 9.6
see also individual disorders
ceroid lipofuscinosis 211
Table 6.5, 266, 299
Charcot-Bouchard aneurysms 189
Chiari malformation 140
Table 4.3, 307
chlorpromazine 91, 96
cholecystokinin (CCK) 77
Table 3.1, 80, 109, 237 & Table 7.2
choline acetyltransferase (ChAT) 90, 91 Fig. 3.10
chorea 63, 114, 130
see also Huntington's disease
choroid plexus 7, 105 & Table 3.6
chromosomal abnormalities 140, 141 Table 4.4
chronic fatigue syndrome 137-138
cingulate gyrus 3, 4 Fig. 1.2, 33 Fig. 1.14, 34 & Fig. 1.15, 38-39, 63

- circle of Willis 5
- 'clasp-knife' response 59
- clomipramine 106, 107, 139
- clonidine 100 Table 3.5, 101, 102, 125 Table 4.2, 132
- clozapine 96 & Table 3.4, 97, 106
- cluster headaches 124, 125 Table 4.2
- CNQX 81, 82 Fig. 3.6
- cocaine 94-95, 97
- cochlear nuclei 20 & Fig. 1.10, 67
- coma 19, 39, 70, 144, 167, 254, 261, 263-264
- computerised tomography (CT) 264, 265, 302, 308, 311
- brain imaging 303, 304 Figs 9.1-9.2
- indications for 121-122
- spine imaging 306
- trauma and 169, 170, 304 Fig. 9.1, 309-310 & Fig. 9.7
- confabulation 38, 136, 171, 175
- confusional states/delirium 119, 122, 134, 135 Box 4.6, 149, 198
- congenital disorders/malformations 140 Table 4.3, 141, 142 Table 4.5, 214-216 & Table 6.7
- neuroradiology and 306-307 & Figs 9.4-9.5
- congenital insensitivity to pain 58
- constructional apraxia 30 Table 1.4, 120, 157 Table 5.1, 171-172
- contingent negative variation (CNV) 290-292
- convulsants 85 Fig. 3.8, 87 Table 3.2, 88
- corpus callosum 2, 3 Fig. 1.1, 140 Table 4.3, 170
- agenesis 142 & Table 4.5, 214, 307 Fig. 9.4
- cortical blindness 157 Table 5.1, 172
- corticosteroids 230, 242, 243 & Table 7.4
- corticotrophin-like intermediate lobe peptide (CLIP) 223, 224 Fig. 7.1
- corticotrophin releasing hormone (CRH) 77 Table 3.1, 109-110, 235, 236, 237 Table 7.2, 239 & Table 7.3
- cotransmitters 80
- cranial nerve nuclei 8, 22, 23, 24 & Fig. 1.11
- cranial nerves 8-9 & Fig. 1.6 & Table 1.1, 12, 19
- neurological examination and 117-118
- craniopharyngioma 202, 205
- Creutzfeld-Jakob disease 122, 135 Box 4.5, 148, 194 Box 6.3, 197, 200, 255, 258 & Fig. 8.7, 259 Fig. 8.8
- '*Cri du chat*' syndrome 141 Table 4.4
- Cushing's syndrome 243
- cutaneous receptors 50-52
- cyanocobalamin deficiency (Vitamin B12) 210
- cyclic adenosine monophosphate (cAMP) 78 Fig. 3.4, 79, 80, 106, 222, 227 & Fig. 7.3, 231
- Dandy-Walker malformation 142 Table 4.5, 214, 217 Box 6.7
- degenerative disorders 71, 83-84, 136, 138 Box 4.7, 145-148, 198-201 & Table 6.2, 217 Box 6.7
- EEG and 122, 265, 266
- evoked potentials 299-300
- neuroradiology and 312-314 & Figs 9.8-9.9
- see also individual disorders*
- De Lange malformation 142 Table 4.5
- dementia 40, 71, 83-84, 110, 133-134, 186, 201, 210, 309
- causes 135 Box 4.5
- cortical/subcortical 133-134, 135 Box 4.5, 146, 147
- EEG and 251, 265
- frontal lobe 135 Box 4.5, 146, 265
- multi-infarct 174, 193, 265, 309
- neuropsychological testing 119, 172-175
- sleep and 136, 287
- dementia pugilistica ('punch-drunk' syndrome) 199 Table 6.2, 219, 264
- demyelinating disorders 27, 123, 131, 138 Box 4.7, 148-149, 213-214 & Box 4.6
- see also individual disorders*
- depression 74, 80, 98, 108, 110, 138 & Box 4.7, 145, 191, 209
- dementia and 134, 173-174
- EEG and 255, 283, 287, 290
- endocrine system and 243 & Table 7.4, 244 Table 7.5
- 5-HT and 104, 106, 107
- neuropsychological testing 163-164, 173
- noradrenaline and 99, 101, 102, 109
- sleep and 93, 137, 284, 287
- Wilson's disease and 130
- dermatomes 11, 14
- developmental disorders 139-143 & Tables 4.3-4.5, 214-216 & Table 6.7
- Dévic's disease 213
- dexamethasone 243, 244 Table 7.5
- diabetes 189, 207
- diacylglycerol (DAG) 79 Fig. 3.5, 80
- Dichotic Listening Tests 21, 181 Appendix
- dietary deficiency 134, 135 Box 4.5, 138 Box 4.7, 175, 209-210 & Table 6.4, 213 Box 6.6
- diffuse endocrine system 221-222
- digit span 119, 156, 163, 164
- dizocilpine (MK801) 82 & Fig. 3.6, 83
- dizziness/giddiness 138-139
- domperidone 97
- dopamine 74, 75, 77 Table 3.1, 80-81, 93-98 & Figs 3.11-3.12, 99, 228 Box 7.1
- dopaminergic drugs 96-97 & Table 3.4, 131, 132, 133, 147
- Parkinson's disease and 26, 40, 62, 92, 94, 97, 98, 130, 147
- pituitary and 238, 240 Fig. 7.7
- dorsal column/medial lemniscus pathway 11-12 & Fig. 1.7, 13-14, 26, 52
- dorsal column nuclei 11, 12 Fig. 1.7, 52, 54
- dorsal horn 13 Fig. 1.8, 26, 56, 57, 58
- dorsal root ganglia 11, 12 Fig. 1.7, 13 & Fig. 1.8
- Double Simultaneous Stimulation 182 Appendix
- Down's syndrome 140 & Table 4.3, 141 Table 4.4, 145, 198, 199 Table 6.2, 292
- dressing dyspraxia 32, 120
- dynorphin 77 Table 3.1, 108 Table 3.7
- dysarthria 27, 31, 118, 143, 174
- dyscalculia 120, 157 Table 5.1
- dysgraphia 31, 120
- dyskinesias 26, 75, 96, 132-133
- dyslexia 31, 140, 157 Table 5.1
- dysmetria 27, 61
- dysphasia 120, 171, 172, 292
- dysynergia cerebellaris myoclonica 266
- dystonias 26, 75, 130-131
- electrocochleograms (ECOGs) 296, 297 Fig. 8.21, 300
- electroconvulsive therapy (ECT) 98, 101, 106, 122, 255-257
- electroencephalography (EEG) 69, 246-301

- electroencephalography (EEG) (*continued*)
 abnormal EEG 251-254 & Figs 8.4-8.5
 acute/chronic intracerebral pathology and 257-266 & Figs 8.7-8.10
 burst-suppression effect 253-254, 263
 effects of treatment 254-257 & Fig. 8.6
 epilepsy and 122, 128, 129, 247, 251, 254, 266-282 & Table 8.1
 activating procedures 251, 278-279
 hypsarrhythmia 265, 271, 284
 ictal abnormalities 271-275 & Figs 8.11-8.13
 interictal abnormalities 252 Fig. 8.4, 275, 278
 medication and 279-280
 refractory seizures and surgery 280
 seizures in infants 274-275 and violence 280-282
 episodic behavioural changes and 282
 event-related potentials (ERPs) 290-292
 evoked potentials (EPs) 122-123, 246, 290, 292-300 & Figs 8.17-8.23
 indications for 122-123
 major psychiatric disorders and 282-283
 mapping 288-290 & Figs 8.15-8.16
 normal EEG 247-251 & Figs 8.1-8.3
 periodic lateralised epileptiform discharges (PLEDS) 254, 261, 263
 photic stimulation and 251, 253 Fig. 8.5, 255, 278
 sleep and 39, 249, 251, 283-288 & Tables 8.2-8.3 & Fig. 8.14
 electromyography (EMG) 246, 259, 260 Fig. 8.9, 297
 electroretinograms (ERGs) 293, 294 & Fig. 8.18, 295 Fig. 8.19, 300
 11-hydroxysteroid dehydrogenase (11-OHSD) 231 & Fig. 7.5
 emboli 188, 191 Box 6.1, 261
 emotion and motivation 35-38
 encephalitis 121, 122, 127 Box 4.4, 135 Box 4.6, 196-197, 257, 308
 encephalitis lethargica 130, 197
 endocrine system 33 Fig. 1.14, 35, 36, 73, 135 Box 4.5, 221-245
 autocrine/paracrine actions 221, 225, 234, 236, 239
 diffuse 221-222
 disorders of 138 Box 4.7, 227-228, 233 & Table 7.1, 243 & Table 7.4
 endocrine brain 233-234 & Box 7.2
 hormone actions and psychiatry 242-244 & Tables 7.4-7.5
 hormone receptors 225-231 & Figs 7.3-7.4 & Box 7.1
 hypothalamus and 235-237 & Table 7.2
 pituitary and 237-242 & Box 7.3 & Table 7.3 & Fig. 7.7
 regulation 222-225 & Figs 7.1-7.2
 of hormone action 230-232 & Figs 7.5-7.6
 enkephalins 56 & Fig. 2.3, 58, 62, 75, 77 Table 3.1, 108 Table 3.7
 ependymoma 203, 204, 310
 epidural abscess 194
 epilepsy 21-22, 125-129, 143, 149, 190, 201-202, 215, 287
 absence seizures 127-128, 135 Box 4.6, 287
 minor (*petit mal*) 122, 271, 274 Fig. 8.12, 279
 atypical (*Lennox-Gastaut syndrome*) 128, 271, 275
 causes 73, 83, 89, 127 Box 4.4
 classification 126 Box 4.3, 267-270 Table 8.1
 differential diagnosis 129
 EEG and *see under* EEG
 history taking 127
 myoclonic seizures/jerking 23, 258, 259 & Fig. 8.8, 260 Fig. 8.9, 266, 271-272, 275, 278, 286, 295
 partial seizures 125, 272-274, 287
 complex 122, 125, 128-129, 135 Box 4.6, 272-274, 276-277 Fig. 8.13, 279, 281-282
 post-traumatic 145, 218, 219, 264
 pseudoseizures 126, 266, 279, 280
 temporal lobe 83, 128, 136, 161, 202, 281, 304, 305, 314
 tonic-clonic seizures (*grand mal*) 271, 272 Fig. 8.11, 273 Fig. 8.11, 275, 278, 282, 287
 treatment 84, 129, 279-280
 violence and 38, 128-129, 280-282
 episodic dyscontrol 38, 128-129, 282
 ethanol 85 Fig. 3.8, 88, 207
 excitatory amino acids (EAAs) 58, 62, 81-84 & Fig. 3.6, 89, 90
 extradural haemorrhage 192, 218
 facial nerve 8 Fig. 1.6, 9 Table 1.1, 12, 14
 fasciculation 22, 23 Table 1.3
 fatigue 137-138 & Box 4.7
 feeding 35, 36, 105, 109, 236-237 & Table 7.2, 242
 fibrillation 22, 23 Table 1.3
 finger agnosia 120, 182
 Appendix
 Finger Oscillation Test 181
 Appendix, 183 Appendix
 Finger Tip Number Writing 181 Appendix
 5 α 3 β -pregnanolone 85 Fig. 3.8, 87 Table 3.2, 88
 5-hydroxyindole-acetic acid (5-HIAA) 103 Fig. 3.13, 104
 5-hydroxytryptamine (5-HT) 73, 77 Table 3.1, 99, 102-107 & Fig. 3.13, 228 Box 7.1
 Raphé nuclei and 40, 56 Fig. 2.3, 58, 62
 serotonergic drugs 105 Table 3.6
 flumazenil 87 & Table 3.2, 89-90
 fluoxetine 104, 107
 foetal alcohol syndrome 142, 207
 folic acid deficiency 210
 forebrain 2
 functional organisation 27-41 & Figs 1.13-1.15 & Table 1.4
 fornix 3 Fig. 1.1, 33-34 & Figs 1.14-1.15, 38, 136
 fragile X syndrome 140 & Table 4.3, 141 Table 4.4
 free nerve endings 10, 52, 55
 frontal eye fields 19, 29 & Fig. 1.13, 66
 frontal lobe 2, 3 Fig. 1.1, 6, 28, 128, 157 Table 5.1, 162, 170
 dementias 135 Box 4.5, 146, 265
 functions and neuropsychological examination 120-121 & Fig. 4.1
 gait disturbance 27, 114, 122, 147, 174
 galactorrhoea 95, 97
 galanin 237 Table 7.2, 240 Fig. 7.7, 242
 Galveston Orientation and Amnesia Test (GOAT) 168
 gamma-aminobutyric acid (GABA) 49, 56 & Fig. 2.3, 58, 61, 62, 72, 77

- Table 3.1, 81, 84-90 & Figs 3.7-3.9 & Table 3.2, 99, 226
- gamma-vinyl GABA 84 & Fig. 3.7
- Gaucher's disease 211 Table 6.5
- Gélineau's syndrome 137
- genes 227
- aberrant expression in disease 224-225 & Fig. 7.2
- control of transcription 222-223
- gepirone 105 & Table 3.6
- Gerstmann's syndrome 30 Table 1.4, 120
- glial cells 71, 73, 74
- glioblastoma multiforme 204
- glioma 202, 203 Box 6.5, 264, 304 Fig. 9.2, 311
- gliosis 123, 135 Box 6.5, 145, 187, 213
- glossopharyngeal nerve 8 Fig. 1.6, 9 Table 1.1, 12, 14
- glutamate 50, 58, 62, 73, 77 Table 3.1, 81-83 & Fig. 3.6, 84 & Fig. 3.7, 129
- glycine 49, 77 Table 3.1, 80, 82 & Fig. 3.6, 83, 84, 226
- G proteins 75, 77 Table 3.1, 78-80 & Figs 3.4-3.5, 89, 91, 100, 104, 106, 226-227 & Fig. 7.3 & Box 7.1, 231, 240
- clonal abnormalities of function in endocrine tumours 227-228
- growth hormone (GH) 97, 101, 194 Box 6.3, 205, 228, 232, 233 Table 7.1, 239-242 & Table 7.3 & Fig. 7.7, 284
- growth hormone releasing hormone (GRF) 237 Table 7.2, 239 Table 7.3, 240-241, 242
- guanosine triphosphate (GTP) 78, 226-227 & Fig. 7.3, 228
- gyri 2, 4 Fig. 1.2
- malformations 215
- habituation 69
- haemorrhage 170, 188, 261, 308
- intracranial 143, 192-193, 218
- spontaneous intracerebral 189, 193
- subependymal plate 217 *see also* subarachnoid haemorrhage; subdural haematoma
- haloperidol 132, 147
- Halstead-Reitan Battery 152, 155, 156, 158, 161, 162, 182-184 Appendix
- Harris Test of Lateral Dominance 181 Appendix
- headache 123-124 & Table 4.1, 125 Table 4.2, 202
- head injury *see* trauma
- hearing 20-21 & Fig. 1.10, 50, 67-68, 118
- hemianopia 16, 17, 190
- hemiballismus 26, 114-115, 130
- hemicholinium 90, 91 Fig. 3.10
- herpes simplex encephalitis 122, 136, 196, 257
- hindbrain 2, 7
- hippocampus 33-34 & Figs 1.14-1.15, 35, 99, 105 & Table 3.6, 199 & Table 6.2, 202
- long-term potentiation and memory and 38, 50, 73, 82-83, 136
- holoprosencephaly 140 Table 4.3, 215
- homovanillic acid (HVA) 94, 95 Fig. 3.12
- hormone(s) 108-110, 221-245
- actions and psychiatry 242-244 & Tables 7.4-7.5
- common precursors give different 223-224 & Fig. 7.1
- production: control of gene transcription 222-223
- receptors 225-231
- catalytic 229
- cell membrane 225-226
- down-regulation 230-231
- intracellular and nuclear 229-230 & Fig. 7.4
- second-messenger systems 226-229 & Fig. 7.3 & Box 7.1
- subtypes 230
- regulation of action 230-232 & Figs 7.5-7.6
- resistance syndromes 233 & Table 7.1
- with similar actions from different genes 224-225 & Fig. 7.2
- Huntington's disease/chorea 26, 62, 83, 134, 135 Box 4.5, 147-148, 200, 265, 313 & Fig. 9.10
- Hurler's syndrome 211 Table 6.5
- hydranencephaly 140 Table 4.3, 215
- hydrocephalus 8, 124 Table 4.1, 135 Box 4.5, 144, 195, 216, 217 Box 6.7
- neuroradiology 121, 303, 307, 313-314
- normal-pressure 174, 313-314
- hyper-/hyporeflexia 22, 23 & Table 1.3
- hypersomnias 136-137, 236, 287
- hypertension 45, 188-189, 193
- hypertensive encephalopathy 124 Table 4.1, 189
- hyper/hypotonia 22, 23 & Table 1.3
- hyperventilation 128, 129, 139, 251, 278, 279, 283
- hypoglossal nerve 8 Fig. 1.6, 9 Table 1.1
- hypoglycaemia 127 Box 4.4, 135 Boxes 4.5-4.6, 136, 207, 252, 283, 288
- hypothalamus 33 & Fig. 1.14, 35-37, 95, 203, 235-237, 287
- feeding behaviour and 35, 36, 236-237 & Table 7.2, 242
- growth hormone and 240-241, 242
- paraventricular nucleus (PVN) 235, 236, 238, 239 Table 7.3, 242
- pituitary and 234, 237-241, 242
- hypoxia *see* ischaemia
- idazoxan 100 Table 3.5, 101
- impotence and sleep studies 287-288
- infections 135 Boxes 4.5-4.6, 137-138 & Box 4.7, 139, 193-195 & Box 6.3 & Table 6.1
- EEG and 257-259 & Figs 8.7-8.9
- of infant/neonate 195 Table 6.1, 218
- neuroradiology and 308
- parenchymal 196-198 & Box 6.4
- inferior colliculus 2, 3 Fig. 1.1, 20 & Fig. 1.10, 21, 68, 69
- Information Processing Tasks 180-181 Appendix
- inhibition in CNS 71, 72 Fig. 3.2, 73
- lateral 52-53 & Fig. 2.2
- presynaptic 49
- inhibitory amino acids 84-90 & Figs 3.7-3.9 & Table 3.2
- inositolphosphate-3 (IP₃) 79 Fig. 3.5, 80
- in-situ* hybridisation 223, 230, 234 Box 7.2
- insomnia 40, 107, 136, 284
- insulin 225, 228 Box 7.1, 229, 230, 233 & Table 7.1
- insulin-like growth factor (IGF-1) 232, 239, 241
- insulin-like growth factor binding proteins (IGFBP) 232 & Fig. 7.6
- intellectual function, tests of 178 Appendix
- internal capsule 5, 12 & Fig. 1.7, 63, 171, 189

internal carotid arteries 3, 5
 Fig. 1.3, 192, 261
 interventricular foramina 3
 Fig. 1.1, 7 & Fig. 1.5
 intracranial pressure, raised
 19, 39, 124 Table 4.1,
 193, 202, 205-206
 ion channels 49, 52, 74 Fig.
 3.3, 77-78 & Table 3.1
 cell excitability and 42-48 &
 Tables 2.1-2.2 & Fig. 2.1
 receptors linked to 77 Table
 3.1, 81-82 & Fig. 3.6,
 85-87 & Figs 3.8-3.9,
 106, 226
 ion distribution and cell
 membranes 43-44 &
 Table 2.1
 ipsapirone 105 & Table 3.6
 ischaemia/hypoxia 127 Box
 4.4, 135 Box 4.6, 137,
 138 Box 4.7, 206, 217,
 307, 309 & Fig. 9.6
 EEG and 253-254
 focal 190-191 & Boxes 6.1-6.2
 global 190, 202, 208, 217
 Box 6.7
 transient ischaemic attacks
 170, 192, 261, 279

 kainate receptors 77 Table
 3.1, 81
 kernicterus 143, 218
 Klein-Levin syndrome 136,
 287
 Klinefelter's syndrome 141
 Table 4.4
 Klüver-Bucy syndrome 37
 Korsakoff's psychosis/syndrome
 38, 102, 136, 207, 209-210
 Krabbe's leucodystrophy
 211, 212 Table 6.6

 Lacunar disease/state 189
 lamotrigine 129
 language 31-33, 153, 157
 Table 5.1, 161, 304
 tests of function 120, 179-
 180 Appendix
 see also aphasia; Broca's
 speech area; dysphasia
 lateral fissure 2, 3 Fig. 1.1,
 5, 16
 lateral geniculate body (LGB)
 16, 17 Fig. 1.9, 18
 laterality, tests of 181
 Appendix
 L-DOPA 93 Fig. 3.11, 94, 131,
 147
 lead toxicity 208
 Leigh's disease 211-212, 313
 Lennox-Gastaut syndrome
 128, 271, 275
 lentiform nucleus 12 Fig. 1.7,
 25 & Fig. 1.12, 26, 61

 leucodystrophies 212 &
 Table 6.6, 213 Box 6.6,
 299, 300, 307 Fig. 9.5, 313
 Lewy bodies 135 Box 4.5,
 147, 201, 265
 ligands: defined 80
 limbic system 5, 14, 33-41,
 57, 203
 lithium 106, 255, 257
 liver failure 127 Box 4.4, 135
 Box 4.6, 137, 206-207, 252
 locus coeruleus 40, 98, 102,
 109, 198, 199 Table 6.2,
 201
 long-term potentiation (LTP)
 50, 73, 81, 82-83, 89
 L-tryptophan 103-104 & Fig.
 3.13, 106, 107
 lymphoma 196, 203, 204,
 205, 311
 lysosomal storage disorders
 211 & Table 6.5
 lysuride 97, 147

 magnetic resonance imaging
 (MRI) 169, 189, 260,
 302, 307 & Figs 9.4-9.5
 brain 304-305
 indications for 123
 spine 306 & Fig. 9.3
 mammillary bodies 3 Fig.
 1.1, 33 Fig. 1.14, 34 &
 Fig. 1.15, 38, 136
 Marchiafava-Bignami syndrome
 207, 213 Box 6.6, 254
 m-chlorophenylpiperidine
 (mCPP) 105 Table 3.6,
 106, 107
 mechanoreceptors 51
 medial forebrain bundle 33
 Fig. 1.14, 34
 medial lemniscus 11-12 &
 Fig. 1.7, 14, 52, 54
 medial longitudinal fasciculus
 19, 20
 medulla 2, 3 Fig. 1.1, 4, 11,
 66, 206 Table 6.3
 medulloblastoma 203 & Box
 6.5, 204, 311
 megalencephaly 215
 megaloblastic anaemia 210
 melanocyte-stimulating
 hormone (MSH) 108,
 223, 224 Fig. 7.1, 228
 Box 7.1, 238
 memory 92, 102, 133, 161-
 162, 176, 237
 contingent negative
 variation and 291
 limbic system and 38-39
 long-term potentiation and
 50, 73, 82-83, 89
 neurological examination
 and 119-120
 tests 157 Table 5.1, 172-
 173, 179 Appendix
 see also amnesia

 meningioma 121, 202,
 204-205, 264, 311
 meningitis 127 Box 4.4, 135
 Box 4.6, 143, 194-195 &
 Table 6.1, 205, 218,
 257, 308
 mental handicap 128, 140,
 186, 217, 265-266
 mercurial compounds:
 toxicity 208
 mesial temporal sclerosis
 (MTS) 202
 messenger RNA (mRNA) 75,
 76, 223, 224, 230, 234
 Box 7.2
 metabolic disorders 122,
 138 Box 4.7
 EEG and 251-252
 inheritable 211-212 &
 Tables 6.5-6.6
 neuroradiology and 312-
 314
 secondary 206-210 &
 Table 6.4
 metachromatic leucodystrophy
 211, 212 & Table 6.6
 metoclopramide 97
 Meyer's loop 16, 17 & Fig. 1.9
 mianserin 101, 106
 microcephaly 139, 215
 midbrain 2, 3 Fig. 1.1, 5
 middle cerebral artery 5 &
 Fig. 1.3, 6 Fig. 1.4,
 171-172, 189, 190, 260,
 261
 migraine 123-124 & Table
 4.1, 125 Table 4.2, 129,
 261, 263, 279
 monoamine oxidase (MAO)
 94, 95 Fig. 3.12, 98, 99,
 104, 107
 morphine 108 & Table 3.7,
 109
 mossy and climbing fibres
 60-61 & Fig. 2.4
 motor abnormalities and
 sleep 286
 motor cortex 2, 4 Fig. 1.2,
 5, 23-24 & Fig. 1.11, 26,
 27, 29 & Fig. 1.13, 31, 63
 motor neuron disease 110,
 148, 201, 265
 motor restlessness 132
 motor systems 22-27, 33
 Fig. 1.14
 corticospinal and
 corticobulbar tracts
 23-25 & Fig. 1.11, 27,
 63-64
 extrapyramidal systems
 25-26 & Fig. 1.12, 63
 motor neurons, upper (UMN)
 and lower (LMN) 22-25
 & Table 1.3, 26, 27, 116
 regulation of movement
 26-27
 see also reflexes

- movement disorders 27,
 114-117 & Box 4.2,
 129-133
- methyl-phenyl-
 tetrahydropyridine
 (MPTP) 75, 98, 201, 208
- multi-infarct dementia 135
 Box 4.5, 174, 193, 265,
 309
- multiple sclerosis (MS)
 148-149, 187, 213-214,
 217 Box 6.7, 266, 294,
 296, 312 & Fig. 9.8
- multiple system atrophy 201
- muscarinic receptors 77
 Table 3.1, 91, 92 &
 Table 3.3, 93
- muscle tone 115 Box 4.2,
 116
- myalgic encephalomyelitis
 (ME) 138
- myasthenia gravis 75, 138
 Box 4.7
- myelography 306, 311
- naloxone 58, 108 & Table
 3.7
- naltrexone 108-109 & Table
 3.7
- narcolepsy 102, 129, 137,
 279, 284-285
- neoplasms *see* tumours
- neostigmine 75
- Nernst equation 44
- nerve conduction (NC) 246,
 297
- nerve gases 75, 90, 91 Fig.
 3.10
- neural tube defects 140
 Table 4.3, 143, 214, 307
- neurofibromatosis 140 Table
 4.3, 142 Table 4.5, 216
 Table 6.7, 307
- neuroleptic-induced
 movement disorders 75,
 96, 131-133
- neuroleptic malignant
 syndrome 131, 133
- neuroleptics 75, 91, 92, 95,
 96-97 & Table 3.4, 100
 Table 3.5, 101, 106, 255
- neurological tests 181-182
 Appendix
- neuromodulators 80
- neurons
 basic pathology 187-188
 general organisation 71-73
 & Fig. 3.1
- neuropeptides *see* peptides
- neuropeptide Y 80, 236,
 237 & Table 7.2
- neuropsychological assessment
 in clinical practice 158-175
 process of 154-158 &
 Table 5.1
- tests in common practice
 178-185 Appendix
- neuropsychological rehabili-
 tation 165, 175-177
- neuropsychology: history
 152-153
- neuropsychology and psych-
 iatry 151-152
- neurosteroids 85 Fig. 3.8,
 87 Table 3.2, 88
- neurosyphilis 197-198, 257
- neurotensin 80, 237 Table
 7.2
- neurotransmission/neuro-
 transmitters *see* trans-
 mission; transmitters
- nicotine 92 & Table 3.3, 97
 nicotinic acid deficiency 210
- nicotinic receptors 77 Table
 3.1, 91, 92 & Table 3.3
- nigrostriatal tract 26, 62, 95,
 130
- nimodipine 193
- N-methyl-D-aspartate receptors
 (NMDA) 77 Table 3.1,
 80, 81-82 & Fig. 3.6, 83
- nociception *see* pain
- nomifensine 94, 98
- noradrenaline 73-74, 77
 Table 3.1, 80, 93-94 &
 Fig. 3.11, 95 Fig. 3.12,
 98-102 & Table 3.5, 237
 Table 7.2, 240 Fig. 7.7
- noradrenergic drugs 100
 Table 3.5
- Northern blotting 223, 224,
 230, 234 Box 7.2
- novelty detection 69
- nystagmus 27, 61, 117, 118,
 139
- optokinetic 19
- vestibular 67
- obstructive apnoea
 ('Pickwickian syndrome')
 137, 285, 286 Fig. 8.14
- occipital lobe 2, 3 Fig. 1.1,
 6, 65, 157 Table 5.1,
 171, 172
- oculomotor nerves 8 Fig.
 1.6, 9 Table 1.1, 18-19
 & Table 1.2
- olfaction 21-22, 50, 117
- olfactory bulb 8 Fig. 1.16,
 21, 22
- olfactory cortex 4 Fig. 1.2
- olfactory nerve 8 Fig. 1.6, 9
 Table 1.1
- oligodendroglioma 204, 311
- olivary nuclei 22, 27, 67
- opiates 57, 97, 102, 108,
 109, 208, 228 Box 7.1
- opioids, endogenous 77
 Table 3.1, 101, 108-109
 & Table 3.7, 237 Table
 7.2, 240 Fig. 7.7
- optic chiasm 3 Fig. 1.1, 5,
 8 Fig. 1.6, 16-17 & Fig.
 1.9, 65, 203, 205
- optic nerves 8 Fig 1.6, 9
 Table 1.1, 15, 16, 17
 Fig. 1.9, 18 Table 1.2,
 19, 65, 213, 293, 294
- optic radiations 16, 17 &
 Fig. 1.9
- optic tracts 8 Fig. 1.6, 16,
 17 Fig. 1.9
- orientation: neurological
 examination 119
- oxytocin 235, 238 & Box 7.3
- Paced Auditory Serial
 Addition Test 181
 Appendix
- Pacinian corpuscles 10, 52
- pain 10, 13-14, 50, 54-58 &
 Fig. 2.3, 108, 298-299
 descending control of 57, 70
 dual nature 55, 57
 gating 11, 13, 70
 nociceptors 51, 55, 68
 referred 57
 transmitters involved 58
- panic attacks 73, 83, 90,
 102, 109, 283
- papilloedema 118, 124
 Table 4.1, 202
- parahippocampal gyrus 3, 4
 Fig. 1.2, 34 Fig. 1.15, 35,
 199 Table 6.2, 202, 212
- paralysis, flaccid and spastic
 22, 23 & Table 1.3
- parathyroid hormone (PTH)
 224 Fig. 7.2, 228 Box
 7.1, 233 Table 7.1
- parathyroid hormone-like
 peptide (PTHrP) 224-225
 & Fig. 7.2
- parenchymal CNS infections
 196-198 & Box 6.4
- parietal lobe 2, 3 Fig. 1.1,
 6, 32, 115 Box 4.2, 120,
 146, 157 Table 5.1
- parieto-occipital sulcus 2, 4
 Fig. 1.2, 6 & Fig. 1.4
- Parkinsonism 40, 130, 131
 drug-induced 92, 98, 132,
 201, 208
- post-encephalitic 98, 130,
 197, 199 Table 6.2
- Parkinson's disease 63, 102,
 135 Box 4.5, 146-147,
 201, 313
- dopamine and 26, 40, 62,
 92, 94, 97, 98, 130,
 147
- Pelizeus-Merzbacher disease
 212 Table 6.6
- pellagra 210
- peptides 74-75, 77 Table
 3.1, 80, 89, 108-110 &
 Table 3.7, 221-245
passim
- periaqueductal grey matter
 (PAG) 39, 56, 57, 58

- perinatal neuropathology 142-143, 217-218
- peripheral nerve distribution 51, 315-316 Appendix
- perivenous encephalomyelitis 197
- periventricular leucomalacia 217
- phacomatoses 140 Table 4.3, 215, 216 Table 6.7
- phencylidine (PCP) 82 & Fig. 3.6
- phenelzine 99
- phenylketonuria 94, 139
- phenytoin 129, 210, 255
- phosphoinositol (PI) cycle 77 Table 3.1, 79-80 & Fig. 3.5, 91, 100, 105
- physostigmine 90, 91 Fig. 3.10, 92 Table 3.3
- Pick-Niemann disease 211 Table 6.5
- Pick's disease 135 Box 4.5, 146, 200, 265, 312 Fig. 9.9, 313
- picrotoxin 85 Fig. 3.8, 87 Table 3.2, 88
- pirenzipine 242
- pituitary 3 Fig. 1.1, 33 Fig. 1.14, 35
anterior 73, 109, 223, 224 Fig. 7.1, 235, 238-239 & Table 7.3
growth hormone and 239-242 & Fig. 7.7
intermediate lobe 223, 224 Fig. 7.1
posterior 235, 237-238 & Box 7.3
tumours 121, 205, 228, 311
- plain radiographs 302-303, 305
- plaques and tangles 145, 198-199 & Table 6.2, 213-214, 312
- polyamines 82 & Fig. 3.6, 83
- polysomnography 284-288
- pons 2, 3 Fig. 1.1, 5, 12 & Fig. 1.7
- porencephaly 140 Table 4.3, 142, 215, 307
- positron emission tomography (PET) 305
- postcentral gyrus 2, 4 Fig. 1.2, 12 & Fig. 1.7
- post-concussion syndrome 145, 169-170
- posterior cerebral artery 4, 5 & Fig. 1.3, 6 & Fig. 1.4, 172, 206 Table 6.3
- posterior communicating arteries 5 & Fig. 1.3
- posterior inferior cerebellar artery 4, 5 Fig. 1.3
- postmortem examination 186-187
- potassium channels 45, 46, 47, 49, 78
- Prader-Willi syndrome 141 Table 4.4
- precentral gyrus 2, 4 Fig. 1.2, 23, 63
- pregnenalone sulphate 85 Fig. 3.8, 87 Table 3.2, 88
- pretectal area 3 Fig. 1.1, 18, 19
- prion proteins 200, 258
- procyclidine 92 & Table 3.3, 132
- progressive multifocal leucoencephalopathy 187, 197, 213 Box 6.6
- progressive supranuclear palsy 102, 134, 135 Box 4.5, 199 Table 6.2, 201
- prolactin 95, 97, 107, 205, 239 Table 7.3, 280
- pseudodementia 134, 173-174
- pseudoseizures 126, 266, 279, 280
- pyramidal tracts 22, 23-25 & Fig. 1.11, 27, 63
- QNB 91, 92 Table 3.3
- radionuclide imaging 305
- Raphé nuclei 40, 57, 58, 61, 62 & Fig. 2.5, 70, 103, 104-105 & Table 3.6, 107
- readiness potential (RP) 290-291
- receptive amusia 30 Table 1.4, 32
- receptors: classification 75-76, 77 Table 3.1
- red nuclei 25 Fig. 1.12, 26, 27
- reflexes 11, 317 Appendix
auditory 67-68
and motor control 58-64
complexity v speed 64 & Table 2.3
control of 59-64 & Figs 2.4-2.5
motor units 58-59
neurological examination of 115 Box 4.2, 116-117
non-specific sensory responses 68-70
principal postural 318 Appendix
vestibular 66-67
visual 18-19 & Table 1.2, 65-66
- release signs 116-117
- 'respirator' brain 190, 206
- reticular formation 22, 25 Fig. 1.12, 26, 39-40, 65, 67, 249
non-specific sensory responses and 68-70
- pain sensation and 56-57
- retina 15-16, 17 Fig. 1.9, 65
- Revised Token Test 180 Appendix
- Rey Auditory Verbal Learning Test 179 Appendix
- Reye's syndrome 207, 257
- Rey-Osterreith Figure 179 Appendix
- Right-Left Orientation 182 Appendix
- ritanserin 105 Table 3.6, 106
- salaam spasms 265, 271
- sane automatisms 288
- schizophrenia 83, 85, 108, 122, 128, 140, 145, 186, 212-213
dopamine and 95, 96, 97, 98, 131
EEG and 256-257, 282, 290, 292
neuropsychological testing 121, 159-163
positive/negative symptoms 96, 159, 160-162, 212
integrationist model 162
unilateralist model 161-162
- scopolamine 92 & Table 3.3, 110
- scotomata 16, 17, 18, 123
- Seashore Rhythms Test 157 Table 5.1, 183 Appendix
- second messengers 74 Fig. 3.3, 76-80 & Table 3.1 & Figs 3.4-3.5, 226-228 & Fig. 7.3 & Box 7.1
- seizures *see* epilepsy
- selegiline 98, 146
- sensitisation/kindling 80-81
- sensory receptors and signal transduction 50-58 & Figs 2.2-2.3
- sensory systems 10-22 & Figs 1.7-1.10 & Table 1.2 *see also under* reflexes
- septal area 33 Fig. 1.14, 34 & Fig. 1.15, 37
- septum pellucidum 3 Fig. 1.1, 7, 34 & Fig. 1.15
- serotonin *see* 5-hydroxytryptamine
- Shy-Drager syndrome 201
- single photon emission computerised tomography (SPECT) 123, 305, 313
- skull tumours 205
- sleep 93, 240, 241
disorders 136-137, 284-288 & Table 8.3 & Fig. 8.14
EEG and 39, 249, 251, 283-288 & Tables 8.2-8.3 & Fig. 8.14
reticular formation and 39, 40, 68, 69

- sodium channels 44, 46, 47, 81, 106
- sodium pump 45
- sodium valproate 84 & Fig. 3.7, 129
- somatosensory cortex 2, 4 Fig. 1.2, 5, 12 & Fig. 1.7, 14, 28, 29 & Fig. 1.3, 54
- somatosensory evoked potentials (SSEPs) 297-299 & Figs 8.22-8.23, 300
- somatosensory/somaesthetic system 10-14 & Figs 1.7-1.8
- higher-order processing 52-54 & Fig. 2.2
- mechanisms 50-52
- neurological examination 117
- see also* pain
- somatostatin (SS) 62, 239 Table 7.3, 240-241 & Fig. 7.7, 242
- space-occupying lesions 124 Table 4.1, 136, 192, 196, 205-206 & Table 6.3, 264-265
- spatial neglect 120, 157 Table 5.1
- Speech Sounds Perception Test 157 Table 5.1, 161, 182 Appendix
- spina bifida 140 & Table 4.3, 143, 214
- spine imaging 305-306 & Fig. 9.3
- spinothalamic tracts 13-14 & Fig. 1.8
- Standardised Luria-Nebraska Battery 154, 155, 157 Table 5.1, 158, 162, 168-169, 184-185 Appendix
- startle response 68, 69
- steroid hormone receptors 229-230 & Fig. 7.4, 231 & Fig. 7.5
- storage and transport disorders 135 Box 4.5, 139, 187, 211-212 & Tables 6.5-6.6, 215
- stroke *see* cerebrovascular disorders
- Stroop Colour-Word Interference Test 155, 180 Appendix
- Sturge-Weber syndrome 140 Table 4.3, 142 Table 4.5, 216 Table 6.7
- subacute sclerosing pan-encephalitis 196, 259, 260 Fig. 8.9
- subarachnoid haemorrhage 191 Box 6.1, 192-193, 215, 217 Box 6.7, 219, 309
- subarachnoid space 7-8
- subdural empyema 194, 308
- subdural haematoma 121, 144, 192, 263, 264-265
- subependymal plate haemorrhage 217
- substance P 56 Fig. 2.3, 58, 62
- substantia nigra 25 Fig. 1.12, 26, 40, 61, 62 & Fig. 2.5, 95, 147, 201, 208
- subthalamus 25 Fig. 1.12, 26, 62 Fig. 2.5
- sulci 2, 4 Fig. 1.2
- sulpiride 96 & Table 3.4
- superior cerebellar artery 4, 5 Fig. 1.3
- superior colliculus 2, 3 Fig. 1.1, 18, 61, 62 Fig. 2.5, 65, 69
- surgical biopsies 187-188
- synapses 48-50, 73-75 & Fig. 3.3
- syrinxes 214
- Tactual Performance Task 157 Table 5.1, 183 Appendix
- tardive dyskinesia 75, 96, 132-133
- Tay-Sachs disease 211 Table 6.5
- tectum 2, 3 Fig. 1.1, 17 Fig. 1.9, 18-19 & Table 1.2, 22
- temperature sensation 10, 13-14, 51
- temporal gyri 3, 4 Fig. 1.2
- temporal lobe 2, 3 Fig. 1.1, 6, 17, 146, 157 Table 5.1, 203 *see also* epilepsy, temporal lobe
- tetrazepam 99, 133, 147
- tetrahydroaminoacridine (THA) 92
- thalamus 16, 39, 40, 54, 130, 171
- anterior nucleus 33-34 & Figs 1.14-1.15, 38
- control of reflexes and 62 Fig. 2.5, 63
- ventroposterior nucleus 12 & Fig. 1.7, 13 Fig. 1.8, 14, 56
- thermoreceptors 51
- thiamine deficiency 136, 139, 207, 209-210
- 3-methoxy4-hydroxyphenylglycol (MHPG) 95 Fig. 3.12, 99-100
- thrombosis 136, 188, 190-191 & Boxes 6.1-6.2, 259-261, 262 Fig. 8.10
- thyroid stimulating hormone (TSH) 35, 36, 110, 228 Box 7.1, 233 Table 7.1, 235, 239 Table 7.3, 244 Table 7.5
- thyrotrophin releasing hormone (TRH) 77 Table 3.1, 110, 228 Box 7.1, 235, 236, 239 Table 7.3, 244 Table 7.5
- thyroxine 233 Table 7.1, 243 Table 7.4
- torticollis 130, 131, 132
- touch 10, 11-14, 50, 51, 52, 54, 117
- toxic states 122, 135 Boxes 4.5-4.6, 138 Box 4.7, 175, 208-209, 254, 313
- Trail Making Test 155-156, 157 Table 5.1, 171, 180 Appendix, 183 Appendix
- transduction mechanisms 52, 76-80 & Table 3.1 & Figs 3.4-3.5
- transient ischaemic attacks 170, 192, 261, 279
- transmission: general features 73-75 & Fig. 3.3, 80-81
- transmitters 40, 71-111, 234 in basal ganglia 62, 92, 95 classification 76, 77 Table 3.1
- experimental investigation of function 234 & Box 7.2
- pain sensation and 58 *see also individual transmitters*; peptides
- tranylcypromine 99
- trauma, cerebral 21, 83, 124, 127 & Box 4.4, 135 Boxes 4.5-4.6, 138 Box 4.7, 143-145, 192
- acceleration/deceleration injuries 219
- birth and 127 & Box 4.4, 218
- direct impact injuries 218-219
- EEG and 263-264
- neuropsychological rehabilitation 175-177
- neuropsychological testing 159-160, 164-170
- neuroradiology and 169, 170, 304 Fig. 9.1, 309-310 & Fig. 9.7
- secondary changes 219
- tricyclic antidepressants 74, 91, 99, 100 Table 3.5, 101, 104, 243, 255, 257
- trigeminal lemniscus 12 & Fig. 1.7, 14
- trigeminal nerve 8 Fig. 1.6, 9 Table 1.1, 12 & Fig. 1.7, 14
- trochlear nerve 8 Fig. 1.6, 9 Table 1.1, 19

- tuberous sclerosis 140 Table 4.3, 142 Table 4.5, 216 Table 6.7, 265
- tumours 127 Box 4.4, 135 Box 4.5, 138 Box 4.7, 196, 202-205, 215-216 & Table 6.7
 EEG and 264
 endocrine, clonal abnormalities of G protein function in 227-228
 neuroradiology and 121, 303, 310-312
 primary 121, 203-204 & Box 6.5
 PTHrP and 224-225
 secondary 205
 Turner's syndrome 141 Table 4.4
- uncus 2-3, 4 Fig. 1.2, 21-22
- vagus nerve 8 Fig. 1.6, 9 Table 1.1, 12, 14, 105 Table 3.6, 106, 118
- ventricles 7-8 & Fig. 1.5, 160, 205, 212, 215
- vertebral arteries 3-4, 5 Fig. 1.3
- vestibular nuclei 22, 26, 66, 67, 138
- vestibular nystagmus 67
- vestibular reflexes 66-67
- vestibulocochlear nerve 8 Fig. 1.6, 9 Table 1.1, 66, 138
- vestibulo-oculomotor reflexes 66, 67
- violence 104, 107
- epilepsy and 38, 128-129, 280-282
 sleep and 288
- viral encephalitis 196-197 & Box 6.4
- vision 15-20, 28, 50, 117-118, 123-124, 148-149
- eye movements 19-20, 30 Table 1.4, 65, 66, 67, 117, 118
- visual cortex 4 Fig. 1.2, 10, 16, 17-18 & Fig. 1.9, 27, 28, 29 & Fig. 1.13, 65
- visual fields 15, 17 Fig. 1.9, 117-118, 157 Table 5.1
- visual pathway 16-17 & Fig. 1.9, 65
- visual reflexes 18-19 & Table 1.2, 65-66
see also optic nerves
- visual evoked potentials (VEPs) 122-123, 149, 293-295 & Figs 8.17-8.19, 300
- Visual Search Test 180 Appendix
- vitamin deficiency 134, 138 Box 4.7, 175, 209-210 & Table 6.4, 213 Box 6.6
- von Hippel-Lindau disease 142 Table 4.5, 216 Table 6.7
- von Recklinghausen's syndrome 142 Table 4.5, 216 Table 6.7
- Warrington Recognition Memory Test 179 Appendix
- Wechsler Adult Intelligence Scale (WAIS-R) 152, 157 Table 5.1, 168, 171, 172, 174, 178 Appendix, 182 Appendix
- Wechsler Memory Scale (WMS-R) 154, 157 Table 5.1, 168, 171, 175, 179 Appendix
- Wernicke's aphasia 30 Table 1.4, 31
- Wernicke's encephalopathy 136, 207, 209, 254
- Wilson's disease 130, 207, 211
- Wisconsin Card Sorting Test 157 Table 5.1, 161, 162, 171
- writer's cramp 130, 131
- yohimbine 100 Table 3.5, 101
- zimetidine 104